Sandoz settles over US Omidria

  
Generate a summary of this article
Listen to this article
Beta

Sandoz has agreed not launch a generic rival to Omeros’ Omidria (ketorolac/phenylephrine) injectable ophthalmic drug in the US until patent expiry in 2033, by amending its abbreviated new drug application (ANDA) from a paragraph IV to a paragraph III certification. Originator Omeros has agreed to dismiss prior patent-infringement litigation, with Sandoz’ action meaning it will no longer seek US Food and Drug Administration (FDA) approval to market its proposed generic until all seven Omidria Orange Book patents expire.

Sandoz has agreed not launch a generic rival to Omeros’ Omidria (ketorolac/phenylephrine) injectable ophthalmic drug in the US until patent expiry in 2033, by amending its abbreviated new drug application (ANDA) from a paragraph IV to a paragraph III certification. Originator Omeros has agreed to dismiss prior patent-infringement litigation, with Sandoz’ action meaning it will no longer seek US Food and Drug Administration (FDA) approval to market its proposed generic until all seven Omidria Orange Book patents expire.

In response to the dismissal, Omeros said it had concluded all litigation with ANDA filers pursuing Omidria generics, having previously...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.